Simponi (golimumab)

Simponi (golimumab) is a fully human sequence derived IgG1 monoclonal antibody and is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.

Target Antigen: TNF-Alpha

TNF-Alpha is a potent pro-inflammatory cytokine involved in a number of different diseases, playing an integral role in autoimmune diseases. TNF-Alpha molecules are homotrimers and exist either as membrane-bound TNF-alpha on the cell surface (mTNF-Alpha) or, as free molecules in solution (sTNF-Alpha), following cleavage from the membrane by the TNF-Alpha converting enzyme (TACE).

Characterization of Golimumab Innovator and Biosimilar Products

Simponi (golimumab) is a fully human sequence derived IgG1 monoclonal antibody and is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.  The Fab-region of Simponi allows the antibody to form stable complexes with both soluble and transmembrane TNF-alpha.  As a result, several mechanisms of action are proposed including the prevention of activation of TNF receptors on TNF-alpha sensitive cells, direct action as a result of mAb binding and effector function by binding cell-associated TNF-alpha and recruitment of effector molecules.

BioOutsource has extensive experience in the development, optimization, and validation of a wide range of different types of binding assays and immunoassays for Simponi to support the biopharmaceutical industry.  Our off-the-shelf methodologies include assays to evaluate the interaction between the mAb and TNF-alpha, as well as functional activities associated with the primary mechanism of action of Simponi for a range of therapeutic uses. In addition, we also offer a range of platform methods to assess the physicochemical properties and structural attributes of Golimumab innovator and biosimilar products.

BioOutsource also offer a range of testing and development services to support the manufacture of NBE monoclonal antibodies:

Our research and development scientists continue to develop new assays for Simponi (golimumab) biosimilars. If you require a method that is not listed then please contact our scientist to discuss your requirements.

Contact our experts

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy